Cost-Effectiveness Metrics Payers Seek for Digital Therapeutics

For patients with interstitial lung disease (ILD), a subsequent diagnosis of pulmonary hypertension substantially increases utilization of healthcare resources as well as costs.

A research team led by University of California, San Francisco, found flaws in how the large language model assessed prevalence and made differential diagnoses.

The digital prescription therapeutic AspyreRx, when added to prescription diabetes therapies, can help reduce the costs of managing the disease.

The smartphone app is currently under investigation in the CONVOKE study as a pharmaceutical therapy, aiming to address the negative symptoms associated with adult schizophrenia.

As the only FDA-approved, game-based digital therapeutic, EndeavorRx’s eligibility is expected to more than double the number of pediatric patients with ADHD who have a prescription from a healthcare provider, due to the increased age range.

In response to the high demand for healthcare professionals and over 2 million annual job openings — a 40% growth rate surpassing the average for all other occupations—healthcare organizations are seeking technological solutions to address this pressing issue.